Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$9.86M Sell
74,000
-54,800
-43% -$6.2M 0.96% 30
2026
Q1
$14.3M Buy
128,800
+39,800
+45% +$4.71M 2.21% 16
2025
Q4
$12M Sell
89,000
-16,400
-16% -$1.79M 2.09% 18
2025
Q3
$8.95M Buy
+105,400
New +$6.46M 1.98% 19

Other funds holding ABVX

Apis Capital Advisors's ABVX Position: Q2 2026 in Review

Apis Capital Advisors reduced its Abivax (ABVX) stake by 43% in Q2 2026, selling an estimated $6.2M and leaving 74,000 shares worth $9.86M. The position accounts for 0.96% of the portfolio, ranked #30.

Apis Capital Advisors first reported a position in ABVX in Q3 2025 and has held it in 4 quarters since. The position peaked at $14.3M in Q1 2026. 302 funds tracked by Wall St. Rank hold ABVX as of Q2 2026.

  • Apis Capital Advisors held 74,000 shares of Abivax worth $9.86M as of Q2 2026.
  • Apis Capital Advisors sold 54,800 Abivax shares in Q2 2026, an estimated $6.2M.
  • Abivax made up 0.96% of Apis Capital Advisors's portfolio in Q2 2026, its #30 holding.
  • Apis Capital Advisors first reported a position in Abivax in Q3 2025 and has held it in 4 quarters since.
  • Apis Capital Advisors's Abivax position peaked at $14.3M in Q1 2026.
  • 302 funds tracked by Wall St. Rank held Abivax as of Q2 2026.

Based on Apis Capital Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.